Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01428362 · ClinicalTrials.gov registry record · Phase 2
VI-1121 for the Treatment Alzheimer's Disease
A Phase 2 study of Alzheimers Disease, sponsored by VIVUS.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
- 11
- Study locations
NCT01428362 is a Phase 2 study of Alzheimers Disease that has completed, run by VIVUS. The registered enrollment target is 61 participants, below the 4,061-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (98% lower). The trial reports 11 study locations across 9 states.
The verdict
NCT01428362, a Phase 2 study of Alzheimers Disease, has completed, sponsored by VIVUS.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to determine whether VI-1121 is safe, well tolerated, and effective as a daily treatment for Alzheimer's disease that is worsening despite current treatment.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VI-1121
Study Locations (11)
California
- - San Francisco
- - Santa Monica
North Carolina
- - Durham
- - Raleigh
Florida
- - Sunrise
Kentucky
- - Louisville
Nevada
- - Las Vegas
New Jersey
- - Toms River
New York
- - New Windsor
Ohio
- - Toledo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2011-08 |
| Est. Completion | 2013-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01428362
The ClinicalTrials.gov registry entry for NCT01428362 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,061-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (98% lower). The listed sponsor is VIVUS, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01428362 reports 11 study locations spanning 9 distinct geographic areas - top geographies include California, North Carolina, Florida.
Frequently Asked Questions
What is clinical trial NCT01428362 about?
NCT01428362 is a clinical study titled "VI-1121 for the Treatment Alzheimer's Disease". The purpose of this study is to determine whether VI-1121 is safe, well tolerated, and effective as a daily treatment for Alzheimer's disease that is worsening despite current treatment.
What is the current status of trial NCT01428362?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2011-08. Estimated completion is 2013-08.
What conditions does trial NCT01428362 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT01428362?
The interventions under investigation include: Placebo (DRUG), VI-1121 (DRUG).
Who is sponsoring clinical trial NCT01428362?
This trial is sponsored by VIVUS, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01428362 being conducted?
This trial has 11 study locations across California, Florida, Kentucky, Nevada, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
Open-label Extension Study in Participants With Early Alzheimer's Disease
RECRUITING · Phase 2
-
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
RECRUITING · Phase 2
-
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.